International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Update

International Stem Cell Corp. (OTCMKTS:ISCO) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,770 shares, an increase of 178.7% from the July 15th total of 635 shares. Based on an average daily volume of 58,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are sold short.

International Stem Cell Stock Up 12.9%

Shares of OTCMKTS ISCO opened at $0.35 on Friday. The business’s 50 day moving average is $0.22 and its two-hundred day moving average is $0.18. The company has a market cap of $2.80 million, a P/E ratio of -4.38 and a beta of -0.03. International Stem Cell has a 12 month low of $0.12 and a 12 month high of $0.48.

International Stem Cell (OTCMKTS:ISCO) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.01) earnings per share for the quarter. The firm had revenue of $2.67 million during the quarter.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.